A Health Policy Model of CKD: 1. Model Construction, Assumptions, and Validation of Health Consequences

RTI International, Research Triangle Park, NC 27709, USA.
American Journal of Kidney Diseases (Impact Factor: 5.76). 03/2010; 55(3):452-62. DOI: 10.1053/j.ajkd.2009.11.016
Source: PubMed

ABSTRACT A cost-effectiveness model that accurately represents disease progression, outcomes, and associated costs is necessary to evaluate the cost-effectiveness of interventions for chronic kidney disease (CKD).
We developed a microsimulation model of the incidence, progression, and treatment of CKD. The model was validated by comparing its predictions with survey and epidemiologic data sources.
US patients. MODEL, PERSPECTIVE, & TIMEFRAME: The model follows up disease progression in a cohort of simulated patients aged 30 until age 90 years or death. The model consists of 7 mutually exclusive states representing no CKD, 5 stages of CKD, and death. Progression through the stages is governed by a person's glomerular filtration rate and albuminuria status. Diabetes, hypertension, and other risk factors influence CKD and the development of CKD complications in the model. Costs are evaluated from the health care system perspective.
Usual care, including incidental screening for persons with diabetes or hypertension.
Progression to CKD stages, complications, and mortality.
The model provides reasonably accurate estimates of CKD prevalence by stage. The model predicts that 47.1% of 30-year-olds will develop CKD during their lifetime, with 1.7%, 6.9%, 27.3%, 6.9%, and 4.4% ending at stages 1-5, respectively. Approximately 11% of persons who reach stage 3 will eventually progress to stage 5. The model also predicts that 3.7% of persons will develop end-stage renal disease compared with an estimate of 3.0% based on current end-stage renal disease lifetime incidence.
The model synthesizes data from multiple sources rather than a single source and relies on explicit assumptions about progression. The model does not include acute kidney failure.
The model is well validated and can be used to evaluate the cost-effectiveness of CKD interventions. The model also can be updated as better data for CKD progression become available.

  • [Show abstract] [Hide abstract]
    ABSTRACT: AimIt is necessary to screen the people at high risk for proteinuria with an economic, reliable and convenient method. The aim of this study is to establish a new approach to predict 24-hour urine protein (24-hour UP) by routine laboratory assays.Methods Five centers were included and totally 4211 hospitalized patients were enrolled. All samples were assayed for dipstick protein (DSP), specific gravity (SG), 24-hour UP and serum albumin (ALB) simultaneously. 4211 patients were randomly divided into two groups for establishing and testing the equations. Equations were built by multiple log-linear regressions.Results(1) DSP is significantly correlated to 24-hour UP in a logarithmic pattern; (2) SG interprets 24-hour UP for specific DSP; (3) Equation 1 = 0.203 x 10 dummy-variable Fx [100 (SG-1)] -0.470; (4) Equation 2 =13.366 x 10 dummy-variable F x [100 (SG-1)] -0.547 x [ALB (g/L)] -1.130. The dummy-variable F had a point-to-point accordance to DSP (detailed in text).Conclusionscombination of DSP and SG can interpret normal-range proteinuria well; and helped by ALB, their interpretation for macro proteinuria is much improved. It is dependable and economic for routine urinalysis to evaluate pathological proteinuria by equation.
    Nephrology 07/2014; 19(11). DOI:10.1111/nep.12311 · 1.86 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Awareness of chronic kidney disease (CKD), defined by kidney damage or reduced glomerular filtration rate, remains low in the United States, and few estimates of its future burden exist. We used the CKD Health Policy Model to simulate the residual lifetime incidence of CKD and project the prevalence of CKD in 2020 and 2030. The simulation sample was based on nationally representative data from the 1999 to 2010 National Health and Nutrition Examination Surveys. Current US population. Simulation model following up individuals from current age through death or age 90 years. Residual lifetime incidence represents the projected percentage of persons who will develop new CKD during their lifetimes. Future prevalence is projected for 2020 and 2030. Development and progression of CKD are based on annual decrements in estimated glomerular filtration rates that depend on age and risk factors. For US adults aged 30 to 49, 50 to 64, and 65 years or older with no CKD at baseline, the residual lifetime incidences of CKD are 54%, 52%, and 42%, respectively. The prevalence of CKD in adults 30 years or older is projected to increase from 13.2% currently to 14.4% in 2020 and 16.7% in 2030. Due to limited data, our simulation model estimates are based on assumptions about annual decrements in estimated glomerular filtration rates. For an individual, lifetime risk of CKD is high, with more than half the US adults aged 30 to 64 years likely to develop CKD. Knowing the lifetime incidence of CKD may raise individuals' awareness and encourage them to take steps to prevent CKD. From a national burden perspective, we estimate that the population prevalence of CKD will increase in coming decades, suggesting that development of interventions to slow CKD onset and progression should be considered. Copyright © 2014 National Kidney Foundation, Inc. All rights reserved.
    American Journal of Kidney Diseases 11/2014; 65(3). DOI:10.1053/j.ajkd.2014.09.023 · 5.76 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Predicting the timing and number of end-stage renal disease (ESRD) cases from a population of individuals with pre-ESRD chronic kidney disease (CKD) has not previously been reported. The objective is to predict the timing and number of cases of ESRD occurring over the lifetime of a cohort of hypothetical CKD patients in the US based on a range of baseline estimated glomerular filtration rate (eGFR) values and varying rates of eGFR decline.
    International Journal of Nephrology and Renovascular Disease 01/2014; 7:271-80. DOI:10.2147/IJNRD.S58074